Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: A report in a case of delayed graft failure

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 178-181

  Focosi, Daniele ^a   Kast, Richard Eric ^b   Metelli, Maria Rita ^a   Benedetti, Edoardo ^a   Galimberti, Sara ^a   Papineschi, Federico ^a   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1; THIOTEPA; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; BONE MARROW TOXICITY; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DRUG INHIBITION; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; GRAFT FAILURE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; LETTER; LEUKOCYTE COUNT; PRIORITY JOURNAL; PROTEIN DEGRADATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ANTIGENS, CD26; CELL DIVISION; CHEMOKINE CXCL12; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROLYSIS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROTEASE INHIBITORS; PYRAZINES; TRIAZOLES;

EID: 55049091519     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.04.019     Document Type: Letter

References (22)

1. Holst J., and Deacon C. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47 (1998) 1663-1670
2. Augustyns K., Bal G., Thonus G., Belyaev A., Zhang X., Bollaert W., et al. The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr Med Chem 6 (1999) 311-327
3. Oravecz T., Pall M., Roderiquez G., Gorrell M., Ditto M., Nguyen N., et al. Regulation of the receptor specificity and of the function of the chemokine RANTES by dipeptidyl peptidase IV (CD-26)-mediated cleavage. J Exp Med 186 (1997) 1865-1872
4. Van Coillie E., Proost P., Van Aelst I., Struyf S., Polfliet M., De Meester I.H.D.J., et al. Functional comparison of two human monocyte chemotatic protein-2 isoforms, roles of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry 37 (1998) 12672-12680
5. Lambier A., Proost P., Durinx C., Bal G., Senten K., Augustyns K., et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 276 (2001) 29839-29845
6. - human cord blood hematopoietic cells. Exp Hematol 34 (2006) 1060-1068
7. Christopherson Kn, Hangoc G., Mantel C., and Broxmeyer H. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305 (2004) 1000-1003
8. + progenitor cells. J Immunol (2002) 7000-7008
9. Triplitt C., Wright A., and Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy 26 (2006) 360-374
10. Green B., Irwin N., Duffy N., Gault V., and O'harte F.F. PR Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 547 (2006) 192-199
11. Herman G., Stein P., Thornberry N., and Wagner J. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 81 (2007) 761-767
12. Fukuno K., Tsurumi H., Yamada T., Oyama M., and Moriwaki H. Graft failure due to hemophagocytic syndrome after autologous peripheral blood stem cell transplantation. Int J Hematol 73 (2001) 262-265
13. Ishikawa J., Maeda T., Miyazaki T., Manabe N.H.S., Nishiura T., Tomiyama Y., et al. Early onset of hemophagocytic syndrome following allogeneic bone marrow transplantation. Int J Hematol 72 (2000) 243-246
14. Reardon D., Roskos R., Hanson C., and Castle V. Virus-associated hemophagocytic syndrome following bone marrow transplantation. Am J Pediatr Hematol Oncol 13 (1991) 305-309
15. Wu W., Vieira J., Fiore N., Banerjee P., Sieburg M., Rochford R., et al. KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: persistence of infection during hematopoiesis in vitro and in vivo. Blood 108 (2006) 141-151
16. Segovia J.C., Guenechea G., Gallego J.M., Almendral J.M., and Bueren J.A. Parvovirus infection suppresses long-term repopulating hematopoietic stem cells. J Virol 77 (2003) 8495-8503
17. Davies S., Weisdorf D., Haake R., Kersey J., McGlave P.R.N.K., and Blazar B. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 14 (1994) 73-77
18. Min C., Kim D., Lee J., Min W., and Kim C. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation. Acta Haematol 104 (2000) 185-192
19. O'Donghaile D., Hayden P., McCarron S., Doyle E., Lawler M., Browne P., et al. Marrow aplasia developing 13 years after HLA-identical sibling allogeneic transplantation for chronic myeloid leukaemia: successful treatment with antithymocyte globulin and peripheral blood stem cell infusion from the original donor. Eur J Haematol 76 (2006) 258-260
20. Remberger M., Ringden O., Ljungman P., Hagglund H., Winiarski J., Lonnqvist B., et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 22 (1998) 73-78
21. Wolff S. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 29 (2002) 545-552
22. Focosi D., Kast R.E., and Petrini M. Gliptins. Lancet 369 (2007) 269-270